You can return them by: Fax: (02) 8425 4121 Email: [email protected] Mail or in person For any hospital billing enquiries, please contact the NSPH billing department on (02) 8425 3000
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival
Merck & Co/MSD (~75,000 employees) Merck & Co
Expected outcomes: Appetite reduction, 25% waist circumference and weight loss, early visceral fat reduction, improved post-meal glucose responses Expected outcomes: 510% total body weight loss, increased insulin sensitivity, improved energy levels, lowered blood pressure Expected outcomes: Stable lean mass, reduced visceral fat, better metabolic flexibility, readiness to stop medication This programme looks beyond the bathroom scales